Fujitsu and RIKEN develop AI drug discovery technology utilizing generative AI to predict structural changes in proteins
Based on these two technologies, the two parties developed an AI drug discovery technology that can predict structural changes of a protein in a wide range, with the aim of developing next-generation IT drug discovery technology that significantly reduces the development time and cost of drug discovery.
- Based on these two technologies, the two parties developed an AI drug discovery technology that can predict structural changes of a protein in a wide range, with the aim of developing next-generation IT drug discovery technology that significantly reduces the development time and cost of drug discovery.
- Moving forward, Fujitsu and RIKEN will use the newly developed generative AI technology as one of the core technologies for realizing next-generation IT drug discovery technology that can analyze the complex relationships between target proteins and antibodies, and predict global structural changes of molecules with high accuracy and speed.
- To solve this problem, Fujitsu and RIKEN have developed the following two new drug discovery technologies using generative AI.
- Using generative AI technology, Fujitsu and RIKEN analyzed the low-dimensional data and predicted the conformational changes by restoring 3D density maps.